Vivoryon Therapeutics AG plans conversion into Naamloze Vennootschap (N.V.) under Dutch law
Ordinary General Meeting of Shareholders of Vivoryon Therapeutics AG
HALLE (SAALE) / MUNICH, GERMANY, 3 September 2020 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835) invites all shareholders to Vivoryon Therapeutics´ ordinary general meeting of shareholders to be held on Wednesday, September 30, 2020 at 11:00 am CEST, at the registered office, Weinbergweg 22, 06120 Halle (Saale), Germany.
The Meeting will include a proposed resolution to transform Vivoryon Therapeutics into a naamloze vennootschap (N.V) under Dutch law by changing official seat from Halle (Saale) to Amsterdam, the Netherlands.
All relevant documents are available on the company’s website:
With regard to the ongoing COVID-19 pandemic, the company will take various precautionary measures to reduce the risk of infections. The company will provide free of charge hand disinfectant as well as masks to cover the nose and mouth for shareholders and will, subject to the spatial conditions and the number of participating shareholders, arrange the seats with adequate spacing. Additionally, food or beverages will not be offered. The company will strictly monitor the current situation and developments and may adjust measures accordingly.
For more information, please contact:
Vivoryon Therapeutics AG
Dr. Ulrich Dauer, CEO
Gretchen Schweitzer / Joanne Tudorica
Tel: +49 172 861 8540 / +49 171 351 2733
About Vivoryon Therapeutics AG
With 20+ years of unmatched understanding in identifying post-translational modifying enzymes that play critical roles in disease initiation and progression, Vivoryon’s scientific expertise has facilitated the creation of a discovery and development engine for small molecule therapeutics. This platform has demonstrated success by developing a novel therapeutic in type 2 diabetes. In its current programs Vivoryon Therapeutics is advancing its lead product, varoglutamstat (PQ912), in Alzheimer’s disease and its entire portfolio of QPCT and QPCTL inhibitors in oncology and other indications. In addition, the company pursues a development program for Meprin protease inhibitors with potential therapeutic use in fibrotic diseases, cancer and acute kidney injury.
Forward Looking Statements
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgment of Vivoryon Therapeutics AG as of the date of this press release. Such forward-looking statements are neither promises nor guarantees but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.